PRTODAY / NewswireToday Free press release distribution service network

Agency / Source: Bioo Scientific

This article was published free of charge. Only PREMIUM Articles are (Google AdSense™) 3rd party Ads-Free!

Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi - Texas Tech University is using Bioo Scientific’s targeted RNAi delivery agent to deliver an RNAi-based treatment method for HIV infection specifically into T cells
Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi

 

NewswireToday - /newswire/ - Austin, TX, United States, 11/13/2009 - Texas Tech University is using Bioo Scientific’s targeted RNAi delivery agent to deliver an RNAi-based treatment method for HIV infection specifically into T cells.

   
 


Rank or share this free Newswire Press Release Distribution content. Join the network! Learn How!


Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour.


 

Dr Premlata Shankar, Professor and Co-Director, Center of Excellence of Infectious Disease Research at Texas Tech University, who has developed RNAi-based treatment methods for HIV infection, recently entered into a collaborative research agreement with Bioo Therapeutics, a division of Bioo Scientific, to leverage their T3™ technology to facilitate the targeted delivery of siRNA into T cells. Dr. Shankar has already successfully used RNAi to dramatically suppress HIV infection in mice by knocking down three key genes which prevented the HIV infection from spreading.

Bioo Scientific’s T3 Technology will allow Dr Shankar to precisely target the delivery of siRNAs in vivo into T-cells, although it can be used to target any cell type. The patent pending T3 Technology functions by conjugating an RNAi agent carrier to a monoclonal antibody to produce a conjugate, which is then loaded with an RNAi agent such as siRNA or miRNA molecules. The RNAi agent loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by the monoclonal antibody. The RNAi agent is then released to reduce the expression of its intended target. T3 technology can propel the validation of animal experimentation, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.

“I am delighted to join forces with Bioo Scientific in the development of an advanced monoclonal antibody based technology for targeted delivery of siRNA to T cells and potentially other cell types” Dr. Shankar said. “By combining our scientific expertise and resources, we can speed up the development of robust enabling platforms for efficient delivery to desired cells and tissues in vivo which is critical for translating siRNAs into a novel class of drugs to treat human diseases.”

About Bioo Therapeutics
Bioo Therapeutics is a division of Bioo Scientific (biooscientific.com), is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Therapeutics was launched to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases.

 
 


Rank or share this free Newswire Press Release Distribution content. Join the network! Learn How!


Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour.


 

Agency / Source: Bioo Scientific

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
|
Contact: Dawn Obermoeller 
512-301-4094 dawno[.]biooscientific.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bioo Scientific securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSS
AddThis press release: Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAiAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner Twitter /NewswireToday

This article was published free of charge. Only PREMIUM Articles are (Google AdSense™) 3rd party Ads-Free!


Read Latest Articles From Bioo Scientific / Company Profile



Bioo Scientific Launches Two New MaxSignal® Aflatoxin M1 ELISA Kits
MaxSignal® Malachite Green/LMG ELISA Now Included in the USDA’s Chemistry Laboratory Guidebook
NEXTflex™ Modules Lower the Cost of Next Generation Sequencing Sample Prep
Bioo Scientific Simplifies the Analysis of Apoptotic Bodies with the D-Pop™ Kit
Bioo Scientific and Jungwoo F&B to Collaborate to Improve Cancer Diagnosis and Treatment
Bioo Scientific Will Participate in the 2011 AOAC International Annual Meeting
Dr. Masoud Toloue will Describe Methyl-Seq and Small RNA-Seq NGS Library Prep Technologies
Dr Joe Krebs Will Lecture About Melamine Detection in Food At the AOAC Pacific NW Annual Meeting
Bioo Scientific Honored with Export Award
NEXTflex Small RNA Sequencing Kit for NGS Library Prep Launched
Bioo Scientific Launched the AIR™ DNA Fragmentation Kit for Genomic DNA Fragmentation
Bioo Scientific Presented Validation Studies at the Intl Food Safety Conference in Jakarta Indonesia
Bioo Scientific’s New NEXTflex™ Kits Remove PCR Amplification from NGS Library Prep Reducing Bias
Bioo Scientific Launches a Sensitive ELISA for Detection of Melamine Contamination in Food
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA

Reserve This Permanent SPACE

Your LOGO permanently HERE on Newswire Today most visited Page start at $295 per month

 
Sponsored Links


Visit  BizJobs.com

Visit  Koncept Analytics










 
  ©2012 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri- bution today investor relation successful internet entrepreneur free newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)